{
  "ticker": "EPN",
  "pdf_display_url": "https://www.asx.com.au/asx/v2/statistics/displayAnnouncement.do?display=pdf&idsId=02973392",
  "id": "02973392",
  "pages": 9,
  "price_sensitive": true,
  "date": "20250728",
  "time": "1614",
  "pdf_url": "https://announcements.asx.com.au/asxpdf/20250728/pdf/06m6wpk1vx6swn.pdf",
  "summary": "### **Epsilon Healthcare Limited \u2013 Material Information Summary**  \n\n#### **Key Highlights (Quarterly Report & Appendix 4C \u2013 Dec 2024)**  \n- **Capital Raising**:  \n  - $720,000 **equity placement** completed at **$0.016/share**.  \n- **Corporate Restructuring**:  \n  - **DOCA (Deed of Company Arrangement) completed** for subsidiaries **Epsilon Pharma and Epsilon Clinics** (post-voluntary administration).  \n- **Financial Position**:  \n  - **Cash balance**: **$1.565M** (up from $1.213M prior quarter).  \n- **Debt Financing**:  \n  - **$4.6M loan secured** to refinance Bligh Finance debt ($1M from CEO-related entities, $3.6M from Ure Lynam & Co).  \n- **Operational Updates**:  \n  - **Epsilon Pharmacy launch planned for next quarter**.  \n  - **CDMO client engagement resumed**; clinics performance stable.  \n\n#### **Capital Markets Implications**  \n- **High refinancing risk**: Secured loans carry **18% p.a. interest**, maturing **March 2025 (main facility)** and **June 2025 (additional $2.6M facility)**.  \n- **Limited liquidity runway**: **~10.2 quarters of funding** based on current burn rate (negative operating cash flow: **-$154k** for the quarter).  \n\n**Omitted**: Non-material operational details, director commentary, historical reconciliations.  \n\n**Formatting note**: Prioritized trading/capital-sensitive data only, per guidelines. No boilerplate.",
  "usage": {
    "prompt_tokens": 5311,
    "completion_tokens": 342,
    "total_tokens": 5653,
    "prompt_tokens_details": null
  },
  "model": "deepseek/deepseek-chat-v3-0324:free",
  "processed_at": "2025-07-28T06:47:00.312494"
}